Blood-borne Assessment of Stromal Activation in Esophageal Adenocarcinoma to Guide Tocilizumab Therapy

NCT04554771 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

41

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Adenocarcinoma
Oesophageal Adenocarcinoma
Resectable Carcinoma

Interventions

DRUG: Tocilizumab 20 Mg/mL Intravenous Solution
DRUG: Paclitaxel
DRUG: Carboplatin
RADIATION: External beam radiotherapy

Sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Collaborators

[object Object]